Mr A, aged 51 years, has a 27-year history of BD type I. His most recent episode was hypomanic. His illness significantly impaired him over the years, and he had multiple hospitalizations. Over the years, he took various medications, including lithium, carbamezapine, gabapentin, valproic acid, haloperidol, thioridazine, bupropion, fluoxetine, and nortriptyline. On initial presentation, Mr A was taking a combination of venlafaxine extended release (XR) 300 mg daily, mirtazapine 60 mg daily, quetiapine 200 mg daily, and topiramate 100 mg twice daily. His depressive symptoms with concomitant anxiety had stabilized over a 5-month period. He began to experience hypomanic symptoms, scoring 17 on the Young Mania Rating Scale (YMRS) (4), despite increasing his topiramate to 200 mg twice daily. An adjunct mood stabilizer, zonisamide was added at a dosage of 100 mg daily, with the patient giving informed consent for this off-label use. Zonisamide was increased by 100 mg after 2 weeks. At the end of 1 month, the patient was taking 300 mg daily, and his YMRS score was 3. Initially, he experienced sedation but otherwise tolerated the addition of zonisamide without problems. After stabilization, his zonisamide plasma level was 13.8 ug/ml. The topiramate was tapered off over 1 month, with no adverse effects. At 4 months, Mr A remains stable.
Zonisamide has been commercially available in Japan since 1989. It has been studied in an open-label, add-on fashion in the treatment of patients with acute mania. In this group, 33% of patients with bipolar mania showed remarkable improvement, while 80% of patients with BD had more-than-moderate global improvement (5) . Zonisamide is a 1,2benisoxazole-3-methanesulfonamide chemically distinct from other antiepileptic agents (6) . It has several mechanisms of action: it blocks sensitive sodium channels and T-type calcium channels, it scavenges hydroxyl and nitric oxide radicals, and it enhances dopamine function (7) . It also has GABAergic properties (2) and is reported to be structurally similar to serotonin (5). The prescribing information does not give recommendations for monitoring zonisamide, nor does it give a therapeutic range (3). Lepke and others determined that patients taking between 100 and 400 mg daily had plasma levels ranging from 7 to 40 ug/ml, with the mean ranging from 13 to 20 ug/ml (8) . Zonisamide may prove to be a valuable addition to the ever-growing number of mood stabilizing agents used to treat BD, but it needs more controlled study. A case report exists of zonisamide-induced mania in a patient with an underlying seizure disorder and a history of an open head injury (9) . Zonisamide should not be used in patients with a sulfonamide sensitivity, and patients should give informed consent for off-label uses of medications.
Timothy R Berigan, DDS, MD Tuscon, Arizona

Combined Use of Atypical Antipsychotics and Cognitive-Behavioural Therapy in Schizophrenia
Dear Editor:
There are few reports of cognitivebehavioural therapy (CBT) combined with atypical antipsychotic drugs (AAs) in cases of treatment-resistant schizophrenia, especially from North America (1, 2) . Given that AAs improve cognitive function (3), it would be interesting to explore whether AAs complement CBT and whether they can potentiate the effect of CBT. I discuss these issues in the case of a patient with treatment-resistant schizophrenia who was given clozapine and risperidone along with CBT.
Case Report
Mr C, aged 29 years, was diagnosed with paranoid schizophrenia of 9 years' duration. He suffered from auditory hallucinations, somatic passivity, and delusions of persecution, reference, and control. As formally tested, he had poor attention span and impaired verbal working memory. His baseline score on the Positive and Negative Syndrome Scale (PANSS) was 129. Having failed conventional AAs, Mr C was started on clozapine, Can J Psychiatry, Vol 47, No 9, November 2002 W 887
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